Physician profile
Ellen S Marmur
NPI 1134114655
$185,876.54
in general payments reported to CMS, 2019-2025
29 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $43K · 2021: $30K · 2022: $33K · 2023: $1,742 · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $12K · Food and Beverage: $11K · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,875.00 |
| Consulting Fee | $12,180.00 |
| Food and Beverage | $10,510.18 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $63,737.75 | 2019-2024 | Dysport |
| Musculoskeletal Transplant Foundation INC. | $39,824.87 | 2020-2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $34,092.40 | 2019-2025 | |
| Merz North America, INC. | $29,193.72 | 2019-2025 | Xeomin |
| Revance Therapeutics, INC. | $10,798.05 | 2024-2025 | Daxxify |
| Allergan, INC. | $5,810.28 | 2019-2022 | |
| Abbvie INC. | $378.40 | 2021-2025 | |
| Dermavant Sciences, INC. | $210.46 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $204.61 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $204.21 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $170.99 | 2020-2021 | |
| Incyte Corporation | $153.31 | 2022 | |
| Leo Pharma INC. | $148.46 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $142.84 | 2022-2024 | Sotyktu |
| Pfizer INC. | $125.03 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $118.60 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $85.17 | 2023-2025 | |
| Botanix Sb INC | $79.47 | 2025 | Sofdra |
| Lilly USA, LLC | $58.81 | 2024 | Taltz, Ebglyss |
| Journey Medical Corporation | $48.35 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $45.37 | 2022-2023 | Blu-U |
| Aclaris Therapeutics, INC. | $43.92 | 2019 | |
| Genentech USA, INC. | $42.39 | 2019-2020 | |
| Encore Dermatology INC. | $36.68 | 2019-2020 | |
| Epi Health, LLC | $33.07 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.47 | 2022 | |
| Arcutis Biotherapeutics, INC. | $25.54 | 2025 | Zoryve |
| Mylan Pharmaceuticals INC. | $18.88 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Marmur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.